Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
About the study
This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- All participants must have a documented diagnosis of relapse/refractory Multiple Myeloma and have measurable disease as defined per IMWG criteria.
- All participants must have received at least 3 prior lines of MM therapy with IMiD, PI and Anti-CD-38, and progressed on their last therapy (prior BCMA targeted therapy allowed).
- All participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1or 2.
- All participants must have adequate organ function.
- Females of childbearing potential (FCBP) or male participant must agree to follow contraception requirements.
EXCLUSION CRITERIA
Exclusion Criteria:
- All participants with non-secretory MM
- All participants with known auto-immune disease
- All participants with history of life-threatening toxicity related to prior immune therapy.
- All participants with active graft versus host disease after allogeneic stem cell transplantation.
- All participants with active, unstable cardiovascular function.
- All participants with active infection requiring systemic therapy.
- All participants with hypersensitivity to any of the treatments.
- All participants with any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Multiple Myeloma
Age (in years)
18+
Phase
Phase 1/Phase 2
Participants needed
162
Est. Completion Date
Dec 31, 2025
Treatment type
Interventional
Sponsor
iTeos Therapeutics
ClinicalTrials.gov identifier
NCT05289492
Study number
TIG-007
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?